Freenome vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Freenome is a biotech company developing AI-powered multiomics blood tests for early cancer detection; raised $1.1B+ total with Roche as a major investor; signed a $75M exclusive license with Exact Sciences for colorectal cancer;
About
Freenome is a clinical-stage biotechnology company founded in 2014 and headquartered in South San Francisco, California. The company is developing a multiomics blood-based testing platform for the early detection of cancer — combining genomics, proteomics, metabolomics, and epigenomics signals from a single blood draw and applying AI/ML models to distinguish cancer-derived signals from normal biological variation. Its lead program targets colorectal cancer (CRC) screening, aiming to provide a non-invasive alternative to colonoscopy for the millions of Americans who decline or delay guideline-based screening.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.